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The time to ANC 500 ranged from 8 to 19 days with a median
of 10 days. The median length of stay was 21 days. Three patients
experienced early treatment-related mortality. With median follow
up of 21 months, 45 patients have relapsed. The ﬁve year disease
free survival (DFS) is 26% and overall survival (OS) is 58%.
Thirty-nine patients (44%) remain alive and disease free. There
was no difference in DFS (P  .82)or OS (p  .55) between those
patients who received 4 cycles of VAD compared to those who
received any other number of VAD cycles. There appears to be no
advantage to giving anything more than 4 cycles of VAD before
proceeding to stem cell transplant.
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THALIDOMIDE MAINTENANCE AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION FOR MULTIPLE MYELOMA
Grosskreutz, C.L., Egan, R., Scigliano, E., Fruchtman, S.M., Isola,
L.M. Mount Sinai Medical Center, New York, NY
Autologous stem cell transplantation (ASCT) for multiple my-
eloma (MM) results in a slow and progressive decline in progres-
sion free survival. Thalidomide is an effective salvage agent in
patients who relapse with MM after ASCT and produces no my-
elosuppression. Therefore, it is an attractive drug for maintenance
post-ASCT. We gave thalidomide to 21 patients after ASCT for
MM. Patients received therapy with VAD chemotherapy until
maximal response (maximum 4 cycles), mobilization with cyclo-
phosphamide 4000 mg/m2 and G-CSF 10 mcg/kg/day and autol-
ogous collection followed by ASCT after high dose chemotherapy
with melphalan 200 mg/m2. The median age was 57; the M/F ratio
was 1.6/1. Thalidomide was started upon recovery of counts but no
earlier than day 30 post-ASCT. The initial dose was 200 mg QD
and it was incremented by 200 mg every 2 weeks to a maximum of
800 mg QD. Patients who reported intolerance to the higher dose
were tapered to the prior highest tolerated dose and maintained on
it. The monoclonal gammopathy was IgG in 20 patients and Ig A
in 1 patient. Eleven patients underwent one ASCT and 10 had
tandem transplants. The highest sustained dose of thalidomide was
800 mg and the median was 200mg. Therapy was given for 85 to
1306 days (median 357). The median time of follow up was 474
days (range 131 to 2842). The median pre-ASCT, pre-thalidomide
and post-thalidomide monoclonal immunoglobulin (Ig) levels were
1320 mg/dl, 1200 mg/dl and 1430 mg/dl respectively. For those
progresing on thalidomide the average increase on Ig level was
49.9%. In the entire cohort, 13 patients responded whereas 8
progressed. Thalidomide in a dose of at least 200 mg QD was well
tolerated as maintenance post-ASCT in all patients. However,
several patients (38%) relapsed while receiving the drug. A ran-
domized placebo controlled study, stratiﬁed by known risks for
relapse post ASCT is warranted to determine whether thalidomide
maintenance delays the progression of myeloma after ASCT.
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PRE-APHERESIS THERAPIES AFFECTING CD34 APHERESIS YIELD IN
MULTIPLE MYELOMA PATIENTS
Malone, C.1, Paivanas, N.1, Spiros, A.R.1, Spira, A.I.1, Orloff, G.J.1,
Torloni, S.A.2, Sheridan, M.J.2, Beveridge, R.A.1 1. Fairfax Stem Cell
Transplant Program INOVA Fairfax Hospital Cancer Center, Fairfax,
VA; 2. INOVA Fairfax Hospital, Fairfax, VA
Rationale: We posited that the number of cycles of pre-trans-
plant chemotherapies and/or with radiation (RT) directly impacts
both the procedural CD34 cell yield, and in the number of days
of apheresis required to harvest an overall adequate number of CD
34 cells. Methods: A retrospective analysis of 47 charts from
patients over a 2 year period with multiple myeloma was con-
ducted. We analyzed them for: the type and number of cycles of
chemotherapy, age, sex, and prior radiation therapy. Patients were
sorted into those receiving 4-6 cycles of VAD and those receiving
any other therapies in addition to or instead of VAD. Patients
receiving adjuvant RT similarly divided. Median days-to-adequate-
stem-cell-yield was determined. Cell viability of the apheresis
product was correlated with days-to-white-blood-cell engraftment.
Results: Patients who received VAD only required less apheresis
than those receiving other therapies (median 1 vs. 2 days, p 
0.015). There was no data to suggest that age or sex correlated with
the duration of apheresis. There was no correlation between cell
viability and days-to-white-blood-cell engraftment. Patients re-
ceiving RT in addition to VAD required a median of 1 day of
apheresis. A single patient receiving additional chemotherapy
along with radiation required 4 days of apheresis. Conclusion:
Patients receiving 4-6 cycles of VAD alone had faster adequate
apheresis yields compared with those receiving additional or other
regimens. Radiation did not appear to have an effect on patient’s
CD34 yield who also received VAD as therapy. Further studies
should be pursued to determine the effects of other adjuvant
chemotherapies to VAD, and in patients receiving radiation, in
predicting time to CD34 apheresis yield.
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HLA-MATCHED RELATED (MRD) OR UNRELATED DONOR (URD) NON-
MYELOABLATIVE CONDITIONING AND HEMATOPOIETIC CELL TRANS-
PLANT (HCT) FOR PATIENTS WITH ADVANCED HODGKIN DISEASE
(HD)
Burroughs, L.M.1,2, Maris, M.B.1,3, Sandmaier, B.M.1,3, Leisenring,
W.1,4,5, Jain Stuart, M.6, Niederwieser, D.7, McSweeney, P.A.8,
Chauncey, T.9, Maziarz, R.10, Agura, E.11, Little, M.-T.1, Blume,
K.G.6, Storb, R.1,3, Maloney, D.G.1,3 1. Clinical Research Division,
Fred Hutchinson Cancer Research Center, Seattle, WA; 2. Department
of Pediatrics, University of Washington, Seattle, WA; 3. Department of
Medicine, University of Washington, Seattle, WA; 4. Public Health
Sciences Division, Fred Hutchinson Cancer Research Center, Seattle,
WA; 5. Department of Biostatistics, University of Washington, Seattle,
WA; 6. Stanford University, Palo Alto, CA; 7. University of Leipzig,
Leipzig, Germany; 8. University of Colorado, Denver, CO; 9. Seattle
Veterans Administration Medical Center, Seattle, WA; 10. Oregon
Health & Sciences University, Portland, OR; 11. Baylor University,
Dallas, TX
Patients (pts) with progressive HD following autologous HCT
have limited treatment options and poor prognosis. We evaluated
the utility of nonmyeloablative conditioning and allogeneic HCT
for pts ineligible for high dose conventional allogeneic HCT due
to age and/or comorbidities. Between December 1998 and Octo-
ber 2002, 27 pts (18 MRD, 9 URD) received 2 Gy total body
irradiation alone (n  7 MRD) or with 90 mg/m2 ﬂudarabine (n 
11 MRD, n  9 URD), G-CSF mobilized peripheral blood HCT
and postgrafting immunosuppression with mycophenolate mofetil
and cyclosporine. Median age was 37 (range 21-65) years. Pts were
heavily pretreated and had advanced disease with a median number
of prior regimens of 5 (range 2-9). Most pts had prior radiation
therapy (25/27) and prior high dose autologous HCT (24/27).
Median time between autologous HCT and salvage therapy was 8
(range 2-73) months. Median time between autologous HCT and
allogeneic HCT was 16 (range 2-78) months. At allogeneic HCT,
5 pts were in complete remission (CR), 11 in partial remission
(PR), 4 had relapsed disease and 7 had refractory disease. All pts
engrafted and there were no graft rejections. The overall incidence
of acute Grade II, III, and IV GVHD was 33%, 15%, and 4%
respectively. Incidence of chronic extensive GVHD was 55% at 1
year. The overall response rate, deﬁned as those pts with measur-
able disease prior to transplant who achieved a CR or PR after
allogeneic HCT was 55%. Currently, 9 of 27 pts are alive; 6 are in
CR and 3 have relapsed or have progressive disease (PD), with a
Table. Median Days of Apheresis Required: Patients Receiving VAD
vs. Receiving VAD  Other Adjuvant Therapy
Chemotherapy
Only
Median
Days of
Apheresis
Radiation 
Chemotherapy
Median
Days of
Apheresis
VAD only (n  25) 1 RT  VAD
(n  5)
1
Other (n  22) 2 RT  other
chemo (n  1)
4
Poster Session II
73BB&MT
median follow up of 18 (6-54) months. Eighteen pts have died; 9
from non-relapse causes (8/9 died of infections  GVHD) and 9
from relapse/PD a median of 7 (range 1-38) months post trans-
plant. Day 100 and 1 year NRM was 7% and 35% respectively.
One year overall survival, progression free survival and relapse/PD
incidence were 51%, 18% and 47% respectively. A detailed de-
scription of the MRD and URD pts is shown in Table 1. In
summary, salvage nonmyeloablative conditioning and allogeneic
HCT provides anti-tumor activity in pts with relapsed or refrac-
tory HD who are ineligible for conventional allogeneic transplant.
Future efforts incorporating tumor-speciﬁc antibody therapy after
nonmyeloablative conditioning HCT are being developed in an
effort to improve disease free survival, anti-tumor activity and
overall survival in pts with relapsed or refractory HD.
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RISK-FACTORS OF MELPHALAN/FLUDARABINE DOSE-REDUCED ALLO-
GENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE
MYELOMA
Kroger, N.1, Perez-Simon, J.A.2, Myint, H.3, Klingemann, H.3, Shi-
moni, A.4, Nagler, A.4, Martino, R.5, Allegre, A.6, Tomas, J.7, Schw-
erdtfeger, R.8, Kiehl, M.9, Fauser, A.9, Sayer, H.G.10, Leon, A.11,
Beyer, J.12, Zabelina, T.1, Ayuk, F.1, San Miguel, J.2, Brand, R.13,
Zander, A.1 1. Bone Marrow Transplantation-University Hamburg,
Hamburg, Germany; 2. Hospital Clinico Universitario, Salamanca,
Spain; 3. Dept of BMT, Rush-University Medical Center, Chicago, IL;
4. Bone Marrow Transplantation, Tel Hashomer, Israel; 5. Hosital de la
Santa Creu I Sant Pau, Barcelona, Spain; 6. Hospital de la Princesa,
Madrid, Spain; 7. Fundacion Jimenez Diaz, Madrid, Spain; 8. Bone
Marrow Transplantation, Wiesbaden, Germany; 9. Bone Marrow
Transplantation, Idar-Oberstein, Germany; 10. Dept of Oncology and
Hematology, Jena, Germany; 11. Hospital de la Seguridad Social, Jerez,
Spain; 12. Dept of Hematology and Oncology, Marburg, Germany; 13.
Dept of Medical Statistics, Leiden, Netherlands
To evaluate the impact of timing of dose-reduced allograft in
patients with multiple myeloma, we analyzed 120 patients in a
retrospective study, who were treated with melphalan/ﬂudarabine
as conditioning regimen. The cumulative risk at one year for
treatment-related mortality (TRM) was 18% (95% CI: 12-28%).
In a multivariate analysis, relapse after prior high-dose chemother-
apy was the most signiﬁcant factor for TRM (HR 2.80; 95% CI:
1.16-6.74; p  0.02), relapse (HR 4.14; 95% CI: 2.04-8.38, p 
0.001), event-free (HR 3.11; 95% CI: 1.77-5.46; p  0.001), and
overall survival (HR 2.69; 95% CI: 1.35-5.35; p  0.005). In
addition, relapse was also signiﬁcantly diminished by chronic
GvHD in a time-dependent Cox model (HR 0.37; 95% CI: 0.16-
0.87; p  0.02), while trans-plantation with peripheral blood stem
cells (PBSC) resulted in better overall survival (HR 0.35; 95% CI:
0.14-0.88; p  0.002). In a subgroup of patients with chemosen-
sitivity at time of transplantation and no relapse after a prior
high-dose chemotherapy who were transplanted with PBSC (n 
46), the cumulative risk of TRM at one year was only 8% (95% CI:
1-54%), and the two-year estimated event-free and overall survival
was 60% (95% CI: 42-78%) and 75% (95% CI: 59-91%) for
related (n  34), and 81% (95% CI: 59-100%) and 92% (95% CI:
76-100%) for unrelated donors (n  12). We conclude that dose-
reduced allograft with related and unrelated donors should be
performed at an earlier stage of the disease in patients who are
chemosensitive and without relapse after a prior autograft, result-
ing in a lower TRM and better event-free and overall survival.
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TRANSPLANTATION OF BOYS WITH X-LINKED ADRENOLEUKODYS-
TROPHY WITH UNRELATED-DONOR, PARTIALLY HLA-MISMATCHED
BANKED UMBILICAL CORD BLOOD
Allison, J., Martin, P.L., Szabolcs, P., Driscoll, T., Parikh, S., Wood, S.,
Kurtzberg, J. Duke University Medical Center, Durham, NC
Introduction: X-linked adrenoleukodystrophy causes dysmyeli-
nation and fatal neurodegenerative disease in 30%-50% of affected
patients. Bone marrow transplantation has been shown to prevent
progression of neurologic disease if performed early in the course
of the disease. As some children lack suitably matched bone mar-
row donors, we explored the efﬁcacy of using partially mismatched
unrelated donor umbilical cord blood transplantation to treat this
disease. Methods: Between 11/1996 and 7/03, 10 boys with a
median age of 7 years (range 2-26 years) were prepared for trans-
plantation with busulfan, cyclophosphamide, and ATG and trans-
planted with 4/6 HLA-matched (n  6) or 5/6 (n  4) unrelated
umbilical cord blood. The median cell dose administered by the
graft was 6.84  10e7cells/kg (range 2.83-14.19) and median
CD34 dose was 2.42  10e5/kg (range 0.48-5.46). GvHD prophy-
laxis was given with cyclosporine and steroids. All boys received
stress dose steroids as coverage for adrenal insufﬁciency. Support-
ive care consisted of IVIG, empiric antifungals and antivirals, TPN
without intralipids, and G-CSF. Results: All boys engrafted with
donor neutrophils in a median of 22 days (range 13-48) days.
Platelets reached 50K/uL without transfusion support in a median
of 75 days (range 25-227 days). Two patients (20%) had grade
II-IV acute GvHD (both grade IV) and recovered. All patients are
surviving with durable grafts with median EFS of 330 days (range
94-2523 days). All patients had progressive changes on MRI at the
time of transplant. Those transplanted before the onset of signif-
icant clinical symptoms have all done well (n  6) and have not
experienced progression of neurologic disease. These patients have
also demonstrated normalization of nerve conduction studies post
transplant. Four patient had progressive clinical symptoms in the 2
months before transplant. Three of the four progressed post trans-
plant before stabilizing at a lower level of functioning. One patient,
the oldest at transplant, had progressive visual losses but improve-
ment in neuromotor function and peripheral neuropathy. Conclu-
sions: We conclude that unrelated donor, partially mismatched
cord blood is a viable and readily available alternative donor for
patients with X-linked ALD requiring transplantation therapy.
200
DIMINISHED SICKLE CELL ADHESION MOLECULES FOLLOWING BONE
MARROW TRANSPLANTATION (BMT)
Baothman, A.A.1, Kuvibidila, S.R.2, Yu, L.C.2 1. King Faisal Specialist
Hospital & RC, Riyadh, Centeral Province, Saudi Arabia; 2. Louisiana
State University, NewOrleans, LA
To determine whether stem cell allograft affects the expression
and interaction of adhesion molecules on both sickle red cell and
endothelial cells, we examined baseline and follow-up of vascular
Table. Results of Nonmyeloablative Conditioning Followed by
Allogeneic HCT for HD Using MRD or URD
MRD
(n  18)
URD
(n  9)
Median follow up of living
patients (range)
36 (12-54)
months
11 (6-24)
months
Disease status at HCT 4 CR, 7 PR,
4 Rel, 3 Ref
1 CR, 4 PR,
4 Ref
Overall response rate 57% (7 CR,
1 PR)
50% (3 CR,
1 PR)
Living patients/status 3 CR, 2 PD 3 CR, 1 Rel
Acute GVHD grade II, III, IV 33%, 11%, 6% 33%, 22%, 0%
1 year chronic extensive
GVHD
50% 60%
Day 100 NRM 11% 0%
One year NRM 39% 26%
One year overall survival 39% 75%
One year progression free
survival
11% 35%
One year Rel/PD incidence 50% 40%
Rel, relapse; Ref, refractory.
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